Opinion|Videos|January 17, 2025
MAIC Analyses and Bispecific Therapies: Guiding Treatment Decisions in B-Cell Lymphomas
Panelists discuss how comparative data from matching-adjusted indirect comparison (MAIC) analyses guide treatment decisions between bispecific therapies and the insights from MAIC results comparing epcoritamab and glofitamab that may influence therapy selection.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you use comparative data from MAIC analyses to guide treatment decisions between available bispecific therapies?
- What do the results of the MAIC comparing epcoritamab and glofitamab suggest about the relative differences of these agents, and how might these influence therapy selection?
Advertisement
Related to this article
Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
Delphi consensus guides dermatology on spotting CTCL vs atopic dermatitis before/after dupilumab, using biopsy plus T-cell clonality testing and safer treatment switches.
Rosacea is likely missed, not rare, in skin of color, as low suspicion and hard-to-see redness delay diagnosis, said Hilary Baldwin, MD.
Hidradenitis suppurativa diagnosis often takes 7 to 10 years, and patients with skin of color often present with tunnels and scarring already in place.
In HIV, lymphoma survival tracks tumor stage and CD4 count, not viral suppression, a Spanish cohort shows.
Polyphenols show lab promise for endometriosis, but human evidence is thin, and the best resveratrol pain trial was negative.
Those using e-cigarettes were more likely to develop cataracts, and those receiving cataract surgery less likely to develop depression and anxiety.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
2
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
3
Using Complement Inhibitors in GA Comes With Pros and Cons
4
Pairing VYD2311 With mRNA COVID-19 Vaccines: Michael Mina, MD, PhD
5